SB202190 (FHPI)

Catalog No.S1077

SB202190 (FHPI) Chemical Structure

Molecular Weight(MW): 331.34

SB202190 (FHPI) is a potent p38 MAPK inhibitor targeting p38α/β with IC50 of 50 nM/100 nM in cell-free assays, sometimes used instead of SB 203580 to investigate potential roles for SAPK2a/p38 in vivo.

Size Price Stock Quantity  
In DMSO USD 134 In stock
USD 147 In stock
USD 370 In stock
Bulk Discount

Free Overnight Delivery on orders over $ 500
Next day delivery by 10:00 a.m. Order now.

Cited by 38 Publications

Purity & Quality Control

Choose Selective p38 MAPK Inhibitors

Biological Activity

Description SB202190 (FHPI) is a potent p38 MAPK inhibitor targeting p38α/β with IC50 of 50 nM/100 nM in cell-free assays, sometimes used instead of SB 203580 to investigate potential roles for SAPK2a/p38 in vivo.
Targets
p38α [1]
(Cell-free assay)
p38β [1]
(Cell-free assay)
50 nM 100 nM
In vitro

SB 202190 significantly inhibits both basal and anti-Fas antibody-induced MAPKAPK 2 activity in a dose-dependent manner. SB202190 by itself is sufficient to induce cell death in Jurkat and HeLa cells through activation of CPP32-like caspases, which can be blocked by expression of bcl-2. SB202190-induced apoptosis is attenuated by p38β but augmented by p38α. [2] SB 202190 strongly inhibits UVB induced COX-2 protein expression in HaCaT cells, and markedly inhibits UVB induced cox-2 mRNA. [3] SB 202190 treatment inhibits the expression of albumin-induced proinflammatory (monocyte chemoattractant protein-1) and transforming growth factor (TGF)-beta1-induced profibrotic (procollagen-Ialpha1) genes over 50% in renal tubular cells (normal rat kidney-52E). [4] SB 202190 treatment induces phosphorylation of JNK in a dose- and time- dependent manner in A549 cells, induces phosphorylation of ATF-2 transcription factor, and increases AP-1 DNA binding. [6] SB 202190 treatment enhances the growth of THP-1 and MV4-11 cells. SB 202190 increases the phosphorylation of c-Raf and ERK, suggesting that Ras-Raf-MEK-mitogen-activated protein kinase (MAPK) pathway activation is involved in the leukemia cell growth induced by SB 202190. [7]

Cell Data
Cell Lines Assay Type Concentration Incubation Time Formulation Activity Description PMID
HCT-116 MXrGeY5kfGmxbjDBd5NigQ>? MVSyOUDPxE1? NUmwNHRnOzBibXnu MmPOSG1UV8Li NVjRV5pb[XS2ZX71ZZRmeyC2aHWgcXJPSSCjbnSgdJJwfGWrbjDlfJBz\XO|aX;uJI9nKGiERD2yJIlvKHKnc4DvcpNqfmVidH:gSGE> M{TjcFI3OjJ|MkWx
MDA-MB-231 NX:xcmZ2TnWwY4Tpc44hSXO|YYm= MWCyJO69VQ>? NETBNnczPCCq NXXafnFpdGW|c3Xu[ZMhS0OOMjDpcoR2[3Srb36gZpkhXE6IzsG= NFf2dXYzPjFyMEi0PC=>
rBMSCs MmPCSpVv[3Srb36gRZN{[Xl? M4\Pe|ExKM7:TR?= NUnkRYlzOi53IHi= NXPneJhq\GWycnXzd4V{KHSqZTDwbI9{eGixconsZZRqd25ib3[gSXJMKGGwZDDwN|g> NIK2OpozPjB3M{K2Oi=>
MG63 Mnj0SpVv[3Srb36gRZN{[Xl? NHnTc5cyOC9{MD:zNEDPxE1? NGDQdmozPCCq MWnzbYdvcW[rY3HueIx6KGSnY4LlZZNmeyC2aHWgcIV3\Wxib3[gdIhwe3Cqb4L5cIF1\WRicEO4JIlv\HWlZXSgZpkhS2SFbEKgbY4h[SClb37j[Y51emG2aX;uJE1l\XCnbnTlcpQhdWGwbnXy MknMNlU6QTh|MUK=
MG63 MXjBdI9xfG:|aYOgRZN{[Xl? NGPETI4yOC9{MD:zNEDPxE1? NF76e2wzPCCq M172RZNq\26rZnnjZY51dHliZHXjdoVie2WmIITo[UBieG:ydH;zbZMhemG2ZTDv[kBOTzZ|IHnu[JVk\WRiYomgR4REdDJ? M2eyXFI2QTl6M{Gy
HTSMCs M{fIR2Z2dmO2aX;uJGF{e2G7 Ml3YNE4yNzFxMUCg{txO M4\IUlEhcA>? MYjpcohq[mm2ZXSgR29TVS1{LXnu[JVk\WRiSF:tNUBxem:2ZXnuJIxmfmWuczDhcoQhdVKQQTDlfJBz\XO|aX;u MmjqNlU6OjF2NkS=
MIA PaCa-2 NGSzRmtHfW6ldHnvckBCe3OjeR?= MWOyNOKh|ryP NGfSe24zPCCq NH\UNlRz\WS3Y3XkJIxi[3SjdHWgZYNkfW23bHH0bY9vKGmwIHPvcYJqdmG2aX;uJJdqfGhiYn;0bEAzNUSJIHHu[EBFNWGubH;z[eKh MkDaNlU5QDh2OEm=
MIA PaCa-2 MX7GeY5kfGmxbjDBd5NigQ>? MnXNNlDDqM7:TR?= M1TtdlI1KGh? M2HZXJJme3WudIOgbY4h[SCvb3Tld5QhcW6qaXLpeIlwdiCxZjDITWYuOc7zIIDyc5RmcW5iYXPjeY12dGG2aX;u NWXsS4o4OjV6OEi0PFk>
BxPC-3 MmmxSpVv[3Srb36gRZN{[Xl? M335bFIxyqEQvF2= M4XsRVI1KGh? M4DGOZJme3WudIOgbY4h[SCvb3Tld5QhcW6qaXLpeIlwdiCxZjDITWYuOc7zIIDyc5RmcW5iYXPjeY12dGG2aX;u MlHONlU5QDh2OEm=
AsPC-1 MU\GeY5kfGmxbjDBd5NigQ>? M3;n[VIxyqEQvF2= NXrQNo1[OjRiaB?= Ml;2doV{fWy2czDpckBiKG2xZHXzeEBqdmirYnn0bY9vKG:oIFjJSk0y|rFicILveIVqdiCjY3P1cZVt[XSrb36= MV[yOVg5QDR6OR?=
MIA PaCa-2 NIPMS|hHfW6ldHnvckBCe3OjeR?= NF3jXIIzOMLizszN MVqyOEBp NWHWWXhu\W6qYX7j[ZMh[2ynYY\h[4Uhd2ZiUFHSVEB4cGWwIHPvcYJqdmWmIIfpeIgh\2y3Y3;z[UBidmGub3fz M3LFRlI2QDh6NEi5
MIA PaCa-2 MUfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NVLx[4RWOjEEoN88US=> NWPFRYJwOiCq MXTz[Y5{cXSrenXzJINmdGxibHnu[ZMhfG9idILlZZRu\W62IIfpeIghOi2GRzDhcoQhTC2jbHzvd4U> MY[yOVg5QDR6OR?=
BxPC-3 MkDiS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MmC2NlDDqM7:TR?= MmLtNkBp NWjXTJp7e2Wwc3n0bZpmeyClZXzsJIxqdmW|IITvJJRz\WG2bXXueEB4cXSqIEKtSGch[W6mIFStZYxtd3On NFXPUFkzPTh6OES4PS=>
AsPC-1 MmrCS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M4G1OVIxyqEQvF2= M2rsRlIhcA>? M3GzUZNmdnOrdHn6[ZMh[2WubDDsbY5meyC2bzD0doVifG2nboSge4l1cCB{LVTHJIFv\CCGLXHscI9{\Q>? NFT1NpEzPTh6OES4PS=>
HEY NFvHfXJIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NHriUlQzOMLizszN MXmyJIg> NH3CWm1{\W6|aYTpfoV{KGOnbHygcIlv\XNidH:geJJm[XSvZX70JJdqfGhiMj3ES{BidmRiRD3hcIxwe2V? MnLkNlU5QDh2OEm=
OVCAR-3 NHrhVYtIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MoTqNlDDqM7:TR?= MoHsNkBp NEPkbHl{\W6|aYTpfoV{KGOnbHygcIlv\XNidH:geJJm[XSvZX70JJdqfGhiMj3ES{BidmRiRD3hcIxwe2V? M2rYWFI2QDh6NEi5
SK-OV-3 MVTHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NIjDcnozOMLizszN M4nMV|IhcA>? MkK0d4Vve2m2aYrld{Bk\WyuIHzpcoV{KHSxIITy[YF1dWWwdDD3bZRpKDJvRFegZY5lKERvYXzsc5Nm M2HQT|I2QDh6NEi5
MH7A  NGXWRXhIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M{H5V|I1KGh? MVny[Ylv\m:{Y3XzJJRp\SCrbnjpZol1d3K7IHXm[oVkfHNib3[gXGFP MYiyOVg3Ojl4Nh?=
MH7A  NWfNVIc5SXCxcITvd4l{KEG|c3H5 MUSyOUDPxE1? MnvtNlQhcA>? M13kdJJmfmW{c3XzJINmdGxiY4njcIUh[XK{ZYP0JIlv\HWlZXSgZpkhYEGQIHHu[EBk[XW|ZXSgZZBweHSxc3nzJI9nKGOnbHzzJJZq[SCjY4TpeoF1cW:wIH;mJGpPUw>? M3jIUFI2QDZ{OU[2
SCC25 MnvrSpVv[3Srb36gRZN{[Xl? Mk\TNlAh|ryP NHW2O|AzPCCq MYPpcoNz\WG|ZYOgZZV1d3CqYXf5JIxmfmWu MUSyOVg{PDRyMB?=
HaCaT  MXPGeY5kfGmxbjDBd5NigQ>? MljIOUDDvU1? NX25UXZKOjRiaB?= NUjrfmY2cW6qaXLpeJMhUU[QLd8zMYlv\HWlZXSgR2NNOjJicILv[JVkfGmxbjDs[ZZmdHN? Mn74NlU5OzR|NUO=
HaCaT  M2fxU2Z2dmO2aX;uJGF{e2G7 MWW1JOK2VQ>? NVW4OXFOOjRiaB?= NV\VPVFPcW6qaXLpeJMhUU[QLd8xMYlv\HWlZXSgR2NNOjJicILv[JVkfGmxbjDs[ZZmdHN? MVqyOVg{PDN3Mx?=
HPAEpiCs  M{fYdWZ2dmO2aX;uJGF{e2G7 M2f2bVEwOy9zMDFOwG0> NInseXcyKGh? NV[4XXAxemWmdXPld{BUOVBvaX7keYNm\CCLQ1HNMVEheHKxdHXpckBidmRibWLORUBmgHC{ZYPzbY9vKGGwZDDwdo9ud3SncjDhZ5Rqfmm2eR?= MV2yOVc{PDlyMB?=
HPAEpiCs NH7nUZdHfW6ldHnvckBCe3OjeR?= NVjscmgxOS9|L{GwJO69VQ>? MkPINUBp MlrabY5pcWKrdIOgV|FRNXO2aX31cIF1\WRiQXv0JJBpd3OyaH;yfYxifGmxbjCgxsA> MV2yOVc{PDlyMB?=
HPAEpiCs MWrGeY5kfGmxbjDBd5NigQ>? NXXUZZgzOS9|L{GwJO69VQ>? MX6xJIg> MlvPbY5pcWKrdIOgV|FRKHSrbXWt[IVx\W6mZX70cJkhe3SrbYXsZZRm\CClLVr1ckBxcG:|cHjvdplt[XSrb36= NGPVbYQzPTd|NEmwNC=>
K562 M2P2XWZ2dmO2aX;uJGF{e2G7 MX2xNOKh|ryP MlfvNeKhcA>? NUnJU5R2TE2VTx?= NH\TR3lqdmirYnn0d{ByfWmwYXPybY5mNWmwZIXj[YQheDN6IF3BVGsheGixc4Doc5J6dGG2aX;u MXGyOVY5PDB2Mx?=
PANC-1 MYjGeY5kfGmxbjDBd5NigQ>? NH62[JgyOCEQvF2= M3jWbFEhcA>? Moqw[Y5p[W6lZYOgeIhmKGG3dH;wbIFocWNiZX\m[YN1yqB? NEXSXZYzPTZ|MkKyNi=>
BxPC-3 NUe3bWNNTnWwY4Tpc44hSXO|YYm= MWSxNEDPxE1? MlHkNUBp M4Ds[oVvcGGwY3XzJJRp\SCjdYTvdIhi\2mlIHXm[oVkfMLi M3vRVFI2PjN{MkKy
K562  NV;1bFdqTnWwY4Tpc44hSXO|YYm= NEPXcVIxNjJ3LUGg{txO NHu1PW0zPCCq MX;zeZBxemW|c3XzJJJme3[ncnH0do9tNWmwZIXj[YQhUDKDWDDwbI9{eGixconsZZRqd25? M2\Vb|I2PjF7M{my
THP-1 MV7GeY5kfGmxbjDBd5NigQ>? NIKwWZU2KML3TR?= M1rTSVIhcA>? M1H3c5Nq\26rZnnjZY51dHliYYT0[Y52[XSnczDz[YNz\XSrb36gc4YhUUxvMd8xJIlv\HWlZXSgZpkhOjeRSFPoc4wheGy3czDGV2wuOcLi NIjVd44zPTV7OE[2NS=>
WB M3fXWmZ2dmO2aX;uJGF{e2G7 M2\wdFIx6oDLzszNxsA> MXKzNQKBkW2rbh?= NWTzZ4h6\GWlcnXhd4V{KHSqZTDMVHMuKG:{IFzURU1qdmS3Y3XkJGlNNTZiYX7kJHRPTi4QsdMgdJJw\HWldHnvci=> Mk\0NlU2OzB4OEK=
RAW 264.7 M3LYUGZ2dmO2aX;uJGF{e2G7 Mkn5NVDDqM7:TR?= MkSzN|DjiImvaX6= MVXpcoR2[2W|IHPoZZJi[3SncnnzeIlkKH[jY4XvcIF1cW:wIH;mJG9Ee8Li M{CzZ|I2PDZzM{m5
RAW 264.7 NHLrb5FHfW6ldHnvckBCe3OjeR?= NHTGcmgyOMLizszN NFzMfpE{OOLCiX3pci=> NF[4NWNifHSnboXheIV{KHSqZTDl[oZm[3S|IH;mJG9RTyCxbjDvd5Rmd2OuYYP0JJJmfHKjY4Tpc44> MnLvNlU1PjF|OUm=
HaCaT  NEjvblhHfW6ldHnvckBCe3OjeR?= MWi0NOKh|ryP NIP2ZoQ{NTJ2IHi= MXrEUXNQ NXLYfVJNemWmdXPld{B1cGViYXPjeY12dGG2aX;uJI9nKFqRLUG= MYSyOVQ{PTR6NR?=
H9c2 MnjMSpVv[3Srb36gRZN{[Xl? M1HCPVUxyqEQvF5CpC=> NWPIeZBHOTJiaB?= MXXy[YR2[2W|IFzETEBz\WynYYPlJIFv\CCPTWCgcI9{ew>? NWXYOYFGOjV{NEW4NVg>
HSCs NEnORYtCeG:ydH;zbZMhSXO|YYm= MViyOUDPxE1? Ml;pNlTDqGh? MVnzbYdvcW[rY3HueIx6KGG2dHXueYF1\XNiVFetbY5lfWOnZDDhZ5RqfmG2ZXSgTHNEeyCjcH;weI9{cXN? NE\mWYQzPDl4MUm1NC=>
THP-1 MWrHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MWm3NkBp NGLVR25FVVOR NVG4VFFCUUN3ME20MlfPxE1? MViyOFgyPTB6Nx?=
MDDCs M{XB[mdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NVnH[XNxPzJiaB?= NGK0ZnBFVVOR NX\NW41YUUN3MEKuO:69VQ>? NUPOPHhyOjR6MUWwPFc>
MDDCs M{jGPWZ2dmO2aX;uJGF{e2G7 MknRNE0yPSEQvF2= NV;GN3JDPDhiaB?= NYDIU5dMTE2VTx?= MWrzeZBxemW|c3XzJGlHVi4QsTDhcoQhUVBvMUCgdJJw\HWldHnvcuKh M4nrcVI1QDF3MEi3
MDDCs NHLYcVlHfW6ldHnvckBCe3OjeR?= M2TYSVAuOTVizszN NEPUNHM1QCCq NXHzWmtRTE2VTx?= NXHmfopKcW6qaXLpeJMhVUmSLUHhMEBOUVBvMXKgZY5lKFKDTmTFV{Bxem:mdXP0bY9v M2rRNlI1QDF3MEi3
MDDCs MWPGeY5kfGmxbjDBd5NigQ>? NHzyUnMyOCEQvF2= M2TLXFMvPSCq NITRXGNFVVOR MYTicI9kc3NiRVLPWkBIWCxiYoX0JI5wfCCYU2[gS{Bu\WSrYYTl[EBmdnS{eTDpcpRwKGi3bXHuJG1FTEO| M1vnflI1QDF3MEi3
macrophages MlfqSpVv[3Srb36gRZN{[Xl? MnXDNgKBkc7:TR?= NUfpW5JmPC534pEJbC=> MnXMZ49ueGyndHXsfUBqdmirYnn0d{BOXC2LSVmtbY5lfWOnZDDhZ5RqfmG2aX;uJI9nKE6ILd86Ri=> NYLPSYhvOjR6MEi2N|M>
PDL  MWfGeY5kfGmxbjDBd5NigQ>? MkPqNlDDqM7:TdMg NVnkVotjOzBibXnu MWjEUXNQ M1vJR5Nq\26rZnnjZY51dHliaX7obYJqfHNidHjlJJRmdnOrbHWg[o9z[2VvbXXkbYF1\WRiQl3QMVIh\XiycnXzd4lwdg>? MWWyOFU3OTB6MR?=
AGS MVLGeY5kfGmxbjDBd5NigQ>? M33ZSVUh|ryP MnHRN|AhdWmw M{i1[pN2eHC{ZYPz[ZPDqDFvaX7keYNm\CClYYPwZZNmNThiYX7kJINie3Cjc3WtN{Bi[3SrdnH0bY9v MoHKNlQ2PDd6N{i=
H520 NEHYU5FHfW6ldHnvckBCe3OjeR?= M4PSfFExyqEEtV2= MWixJIg> MmPmSG1UVw>? NX3TZ3Fs\GWlcnXhd4V{KHSqZTDw[Y1mfHKneHXkMYlv\HWlZXSgUXNJOiCvUl7BJIFv\CCycn;0[YlvKGyndnXsdy=> MlXjNlQ2OzB2N{W=
H1703 NEDpSXpHfW6ldHnvckBCe3OjeR?= NGDSXVQyOMLiwsXN MmLYNUBp MoLHSG1UVw>? NFKyVXFl\WO{ZXHz[ZMhfGinIIDlcYV1emW6ZXStbY5lfWOnZDDNV2gzKG2UTlGgZY5lKHC{b4TlbY4hdGW4ZXzz MV:yOFU{ODR5NR?=
H520 NWC3fXlKTnWwY4Tpc44hSXO|YYm= MYmxNOKhyrWP M4jPTFEzKGh? MYLEUXNQ MkPjbY5pcWKrdIOgdIVu\XS{ZYjl[E1mdGmlaYTl[EBOW0h{IIDyc5RmcW5ic4ThZoltcXS7 MYKyOFU{ODR5NR?=
H1703 MofVSpVv[3Srb36gRZN{[Xl? NXfCd|ZjOTEEoNM1US=> NFXLcogyOiCq NILPS2VFVVOR MYjpcohq[mm2czDw[Y1mfHKneHXkMYVtcWOrdHXkJG1UUDJicILveIVqdiC|dHHibYxqfHl? NY\JZ4RPOjR3M{C0O|U>
H520 MlTXSpVv[3Srb36gRZN{[Xl? M3[ydFExyqEEtV2= NX\QdmI2PiCq MoTvSG1UVw>? NIr1cpB{cWewaX\pZ4FvfGy7IHnuZ5Jm[XOnczD0bIUhdGW4ZXzzJI9nKHWkaYH1bZRqdi2lb37qeYdifGWmIF3TTFIhcW5icHXt[ZRz\XinZD30doVifGWmwrDj[YxtKGyrbnW= Mo\kNlQ2OzB2N{W=
H1703 MV3GeY5kfGmxbjDBd5NigQ>? NXXkVWFpOTEEoNM1US=> NF\WcII3KGh? NV7veJB2TE2VTx?= MmXod4lodmmoaXPhcpRtgSCrbnPy[YF{\XNidHjlJIxmfmWuczDv[kB2[mmzdXn0bY4u[2:waoXnZZRm\CCPU1iyJIlvKHCnbXX0doV5\WRvdILlZZRm\MLiY3XscEBtcW6n NYfXc4xjOjR3M{C0O|U>
MC3T3-E1 NVHFWHh6TnWwY4Tpc44hSXO|YYm= NHPHd2gxNjNxMz:zNEDPxE1? MmDiNUBp MmHQZZR1\W63YYTld{BVVkZvzsGtbY5lfWOnZDDNUXAuQSCneIDy[ZN{cW:wIHnuJIEh[2:wY3XueJJifGmxbj3k[ZBmdmSnboSgcYFvdmW{wrC= NX3LO4ozOjR3MEK2PVY>
MC3T3-E1 NF7LV5FHfW6ldHnvckBCe3OjeR?= MYizNEDPxE1? MlrvNUBp NYLiVmNb[XS2ZX71ZZRmeyCWTl[t{tEue3SrbYXsZZRm\CCyM{igUWFRUyCyaH;zdIhwenmuYYTpc44> MoX1NlQ2ODJ4OU[=
HUVECs  M2TQN2Z2dmO2aX;uJGF{e2G7 M{XVOVExyqEEtV2= Moi2NUBp Ml;3bY5pcWKrdIOgWG5HNc7zLXnu[JVk\WRiQ2jDUFEheHKxZIXjeIlwdg>? NFTsUWIzPDR6N{m2OC=>
AGS  M2W4O2Z2dmO2aX;uJGF{e2G7 NVfhcnFROTEEoNM1US=> M1n0S|MxyqCvaX6= NYS5fZF6cW6qaXLpeJMhUUxvMd8yMYlv\HWlZXSgZYN1cX[jdHnvckBw\iCyM{i= NHHiSJozPDR5OU[4NS=>
MKN-45 NUK4bZJqTnWwY4Tpc44hSXO|YYm= Ml\jNVDDqML3TR?= NFHhc24{OMLibXnu MoPNbY5pcWKrdIOgTWwuOc7{LXnu[JVk\WRiYXP0bZZifGmxbjDv[kBxOzh? MVuyOFQ4QTZ6MR?=
AGS  M3vsRmZ2dmO2aX;uJGF{e2G7 M1naXFExyqEEtV2= M37COFMxyqCvaX6= NWDSNJZY[XS2ZX71ZZRmeyCLTD2x{tIucW6mdXPl[EBISSClZXzsJI1q\3KjdHnvckBidmRiaX72ZZNqd25? NXfTUHBJOjR2N{m2PFE>
MKN-45 MYfGeY5kfGmxbjDBd5NigQ>? M3jqdFExyqEEtV2= MlrHN|DDqG2rbh?= MVzheJRmdnWjdHXzJGlNNTIQsj3pcoR2[2WmIFfBJINmdGxibXnndoF1cW:wIHHu[EBqdn[jc3nvci=> NFPGRXgzPDR5OU[4NS=>
AGS  MlPmSpVv[3Srb36gRZN{[Xl? MYmxNOKhyrWP NH7oOZQ{OMLibXnu NUH3SY5je2mpbnnmbYNidnSueTDk[YNz\WG|ZYOgTYwuOc7{LXnu[JVk\WRiTV3QNkBidmRiTV3QPUBuWk6DIHX4dJJme3Orb36= M2Pv[lI1PDd7Nkix
MKN-45 MnzuSpVv[3Srb36gRZN{[Xl? MY[xNOKhyrWP NWDTSIM6OzEEoH3pci=> NIr1UoN{cWewaX\pZ4FvfGy7IHTlZ5Jm[XOnczDJcE0y|rJvaX7keYNm\CCPTWCyJIFv\CCPTWC5JI1TVkFiZYjwdoV{e2mxbh?= NF7HPIczPDR5OU[4NS=>
DCs NF\iUFBHfW6ldHnvckBCe3OjeR?= M4HRSFIxyqEQvF2= MVuxxsBp MVjk[YNz\WG|ZYOgTWwuOTJicILv[JVkfGmxbh?= NXvDNJF4OjR2M{S2N|Y>
HUVEC  NF3nT5lHfW6ldHnvckBCe3OjeR?= NVvOOWlrOjBizsztxsA> MYC1JIg> M1X3XWROW09? MXHy[YR2[2W|IHP5eI9scW6nIHX4dJJme3Orb36gcIV3\Wy|IHnuJIEh[2:wY3XueJJifGmxbj3k[ZBmdmSnboSgcYFvdmW{ MkPVNlQyQDlyNkK=
A 549 MXvGeY5kfGmxbjDBd5NigQ>? MmHaOVAh|ryP MX6xJIg> NHv3coZl\WO{ZXHz[ZMhfGinIHzleoVtKG:oIFnMMVjDqA>? NHfHd3czPDF5OU[4PC=>
H520  MXvGeY5kfGmxbjDBd5NigQ>? MVW1M|ExKM7:TR?= M4D1VFEhcA>? M2LJd2ROW09? NVvLU5Rl\GWlcnXhd4V{KE2VSEKgdJJwfGWrbjDhd{B4\WyuIHHzJI1TVkFibHX2[Yx{KGmwIHfl[ol1cW6rYj3lfJBwe2WmIHPlcIw> NVPmVmV2OjRzM{i5NFM>
H1703  NYjOco8yTnWwY4Tpc44hSXO|YYm= M3;TdVUwOTBizszN MVuxJIg> NIrvfI5FVVOR MWXk[YNz\WG|ZYOgUXNJOiCycn;0[YlvKGG|IIflcIwh[XNibWLORUBt\X[nbIOgbY4h\2WoaYTpcoljNWW6cH;z[YQh[2WubB?= MkO4NlQyOzh7MEO=
H520  M2jTbGZ2dmO2aX;uJGF{e2G7 NV[5V4pZOTEEoNM1US=> MVOxNkBp M3\hTWROW09? M3LhSIRm[3KnYYPld{BOW0h{IH3SUmEh[W6mIIDyc5RmcW5ic4ThZoltcXS7IHnuJIdm\mm2aX7pZk11emWjdHXkJG5US0yFIHPlcIx{ M33seFI1OTN6OUCz
H1703  NE\N[4dHfW6ldHnvckBCe3OjeR?= M4O1WlExyqEEtV2= MX2xNkBp M4PqSWROW09? NF7O[Jdl\WO{ZXHz[ZMhVVOKMjDtVm5CKGGwZDDwdo91\WmwIIP0ZYJqdGm2eTDpckBo\W[rdHnubYIufHKnYYTl[EBPW0OOQzDj[Yxtew>? NXvEVVJGOjRzM{i5NFM>
MCF-7  NWTpZphDT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NHHVdXMyOMLizszN NXXVV4VxOjUEoHi= NWPBXYpKcW6qaXLpeJMhfGinIFPSNVA5NWmwZIXj[YQh[2WubDDk[YF1cA>? M13PT|I1OTJ6OEWz
HPAEpiCs M3f5VWZ2dmO2aX;uJGF{e2G7 M1zCbFAvOS9zL{GwJO69VQ>? NGrUZogyKGh? MVrpcohq[mm2czDUUmYu|rFvaX7keYNm\CClUFzBNuKheHKxdHXpckBidmRibWLORUBmgHC{ZYPzbY9v Ml3MNlQxPjlzNUi=
podocytes NHLmS4pHfW6ldHnvckBCe3OjeR?= M{nqS|ExyqEQvF2= MnPDNUBp M4XrfIlvcGmkaYTzJHRITs7{MT3pcoR2[2WmIHHjeIl3[XSrb36gc4YheDN6TVHQT{BidmRiRYLrNU8zyqB? MnPDNlQxOzZ{MUK=
MCF-7 M1PUXWZ2dmO2aX;uJGF{e2G7 M4nGc|ExyqEQvF2= NW[2SGVJOSCq Mo\CSG1UVw>? NWDTeow5emWmdXPld{B1cGViV1GtbY5lfWOnZDDwbI9{eGixconsZZRm\CCyM{igUWFRUw>? MWeyOFAyQTB7MB?=
MCF-7 NFfnSY1HfW6ldHnvckBCe3OjeR?= MUGxNOKh|ryP MW[yOEBp MmLYSG1UVw>? NHLSZ3lqdmO{ZXHz[ZMhfGinIGfBMYlv\HWlZXSgZZBweHSxc3nz NXPC[mJlOjRyMUmwPVA>
HAPI M2q1ZmZ2dmO2aX;uJGF{e2G7 M1q4WVExNzJyL{SwxsDPxE1? NXLQbmlMOSCq NFjuU3pqdmirYnn0d{BVS0SGLXnu[JVk\WRicEO4M2pPUyCPQWDLJJBpd3OyaH;yfYxifGmxbh?= MljtNlM6PjlzMkC=
HAPI NHLtT3JHfW6ldHnvckBCe3OjeR?= NYf4T4FoOjEEoN88UeKh NWf2fph1OSCq M3nNTmROW09? NXLmNnc6[XS2ZX71ZZRmeyCWQ1TEMYlv\HWlZXSgZYN1cX[jdHnvckBw\iCrTl;TJIFv\CCycn;keYN1cW:w M{\KTlI{QTZ7MUKw
HepG2 NFXrdmVHfW6ldHnvckBCe3OjeR?= MXuzOVAhdk1? NFrvfXMzPCCq M{DiUIlvcGmkaYTzJJRp\SCmZXf1[Yxqdi2rbnT1Z4VlKGGldHn2ZZRqd25ib3[gdFM5VUGSSx?= MXKyN|k{OzF7OB?=
AGS  NV;3ZlNNTnWwY4Tpc44hSXO|YYm= NUm2dIZlOTEEoN88US=> NYLJV|VUOzBibXnu NF\QN4JqdmirYnn0d{Bk[XOyYYPlMVMh[WO2aY\heIlwdiCjbnSgbY5pcWKrdHnvckBw\iCHUlu= M4PjVFI{QDVyOUm0
HepG2 MVLHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MoXYNE02OCEQvF2= NXPNc45EPDhiaB?= MYLpcohq[mm2czD0bIUheHKxbHnm[ZJifGmxbjDpckBiKGSxc3Wg[IVx\W6mZX70JI1idm6nch?= M{XRdlI{QDB5NUC4
BEL7404 M1HKPGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MYqwMVUxKM7:TR?= MVK0PEBp M13YTIlvcGmkaYTzJJRp\SCycn;sbYZmemG2aX;uJIlvKGFiZH;z[UBl\XCnbnTlcpQhdWGwbnXy NYXkeFA6OjN6MEe1NFg>
HL7702 NYrSSVV1T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MWGwMVUxKM7:TR?= NIX1VXk1QCCq NHvjVVRqdmirYnn0d{B1cGVicILvcIln\XKjdHnvckBqdiCjIHTvd4Uh\GWyZX7k[Y51KG2jbn7ldi=> M1TrZVI{QDB5NUC4
HepG2 Mn76SpVv[3Srb36gRZN{[Xl? NWLrbVJvOC13MDFOwG0> MY[yOEBp NU\pUpBKcW6qaXLpeJMhfGinIIDoc5NxcG:{eXzheIlwdiCxZjDwN|gh\G:5boP0doVidSCycn;0[YlveyCPQWDLRXBMOixiQWTGNkwhVVONMTDhcoQhUFOSMkegbY4h[SCmb4PlMYRmeGWwZHXueEBu[W6wZYK= NYS0UXVlOjN6MEe1NFg>
BEAS-2B M3zPSmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MlfUNVAh|ryP NYrhRmJiOzBibXnu MVvy[ZZmenOnczD0bIUh\GWlcnXhd4Uhd2ZiY3XscEB3cWGkaXzpeJkhcW6mdXPl[EBjgSCKQ1m= NGPtfGYzOzd6NECzOC=>
BEAS-2B M1XzcGN6fG:2b4jpeJkhSXO|YYm= MlXvNVAh|ryP MYSzNEBucW5? MmHobY5pcWKrdHXkJJRp\SCrbnPy[YF{\SCrbjDMSGgh[W6mIFnMMVgh\XiycnXzd4lwdg>? MV6yN|c5PDB|NB?=
BEAS-2B NUL4eHhYTnWwY4Tpc44hSXO|YYm= MkHCNVAh|ryP NGPHVWE{OCCvaX6= MVTk[YNz\WG|ZYOgeIhmKGyndnXsd{Bw\iClYYPwZZNmNTNuIFLh[EBidmRiZnHz Ml;5NlM4QDRyM{S=
H9c2  Ml\nSpVv[3Srb36gRZN{[Xl? M3jF[|AvODFxMD6xM|Eh|ryP MoqxNUBp NXPN[Xdt[XS2ZX71ZZRmeyCWTl[t{tEucW6mdXPl[EBOVVBvOTDlfJBz\XO|aX;uMEBuWk6DIHzleoVteyxiYX7kJJBzd22xdHXyJIFkfGm4aYT5 MUOyN|c4PDJ3Mh?=
H9c2  M3eyZWZ2dmO2aX;uJGF{e2G7 MljVNUDPxE1? MW[xJIg> MorGdoVlfWOnczDUUmYu|rFiZHny[YN1dHlic4TpcZVt[XSnZDDwN|ghVUGSSzDwbI9{eGixconsZZRqd25? M4TGcVI{Pzd2MkWy
U937 MUXGeY5kfGmxbjDBd5NigQ>? MkXBNVDDqM7:TdMg M2n6eFEhcA>? NUTHVXI2[WK{b3fheIV{KHSqZTDjZYZn\WmwZTDl[oZm[3Rib36gUWtRNTFiYX7kJHBROkGlzsGgcXJPSSC2cnHud4NzcXC2aX;uZYwhdGW4ZXzz NH\m[mgzOzdyN{O4Oy=>
U937 MlTKSpVv[3Srb36gRZN{[Xl? M2X1UFExyqEQvF5CpC=> NG\5UnEyKGh? M4HVdIFjem:pYYTld{Bk[W[oZXnu[U1qdmS3Y3XkJG1MWC1zIHTve44uemWpdXzheIlwdiCjbnSgVHAzSWQQsTD1dE1z\We3bHH0bY9v MnnxNlM4ODd|OEe=
U937 MXzGeY5kfGmxbjDBd5NigQ>? M1rMeVExyqEQvF5CpC=> MYKxJIg> MYjzeZBxemW|c3XzJIMuUnWwIHHu[EBEWkWEIIDoc5NxcG:{eXzheIlwdiCrbjDjZYZn\WmwZT30doVifGWmIHPlcIx{yqB? M3vwcFI{PzB5M{i3
A549 MYTGeY5kfGmxbjDBd5NigQ>? MnTmNE4{NzNxM{Cg{txO MkPDNUBp M3PpWpNq\26rZnnjZY51dHliYYT0[Y52[XSnczDBWHDPu1NvbXXkbYF1\WRiQ1;YMVIheHKxdHXpckBidmRibWLORUBmgHC{ZYPzbY9vKGGwZDDwdo9ud3SncjDhZ5Rqfmm2edMg MmrCNlM3QDB4N{S=
A549 NHjh[YxHfW6ldHnvckBCe3OjeR?= MY[xNOKh|ryPwrC= NEnIWGgxNTNyIH3pci=> NYTsT4R3cW6qaXLpeJMhSVSSzsPTJIlv\HWlZXSgdFQzN3B2NDDNRXBMKGGwZDDwN|ghVUGSSzDwbI9{eGixconsZZRqd25? M4rPVlI{PjhyNke0
A549 NILGU41HfW6ldHnvckBCe3OjeR?= MWSxNOKh|ryPwrC= NYW0ZY5mOSCq Mo\ObY5pcWKrdIOgRXRR|rOVIHnu[JVk\WRiTl[t{tpDKHB4NTDzeYJ2dmm2IIDoc5NxcG:{eXzheIlwdiCjbnSgUmYu|rqEIIDyc41wfGW{IHHjeIl3cXS7 MknvNlM3QDB4N{S=
A549 MoLXSpVv[3Srb36gRZN{[Xl? NGjCW5UyOMLizszNxsA> NXrYelNCOSCq MYny[YR2[2W|IFHUVO6{Wy2|dHnteYxifGWmIHPQUGEzKHCqb4PwbI9zgWyjdHnvcuKh Mo[zNlM3QDB4N{S=
A549 NXrSb4Q1TnWwY4Tpc44hSXO|YYm= MnTmNVDDqM7:TdMg NYDxV2pEOSCq NUD4W|Z1emWmdXPld{BCXFEQs2Ot[Y5p[W6lZXSg[Y57gW2jdHnjJIFkfGm4aYT5JI9nKGOSTFGyxsA> NIToUoczOzZ6ME[3OC=>
PC12 MULGeY5kfGmxbjDBd5NigQ>? NY[3[FhGOTBxMkCvOFAh|ryP M{\zS|HDqGh? MVzpcohq[mm2czDKUmsh[W6mIICzPC=> MmX6NlM2QDR|NUe=
HK-2 NYrMW3NMSXCxcITvd4l{KEG|c3H5 MUKyNOKh|ryP NUH5TotOOjRiaB?= M2PjSIlvcGmkaYTzJGVTUyCjbnSgdFM5VUGSSx?= M{PzSlI{PTR|MUWx
H9c2 NFPqUWpHfW6ldHnvckBCe3OjeR?= MYexxsDPxE1? MmnSNUBp MYfy[YR2[2W|IGTOSk3PuS2rbnT1Z4VlKE2PUD25JI1TVkFibHX2[Yx{KGGwZDDwdo9ud3SncjDhZ5Rqfmm2eR?= MlHTNlM{PTN4OUm=
H9c2 M17tOWZ2dmO2aX;uJGF{e2G7 MornNeKh|ryP NEn3cGkyKGh? M4Pwb5Jm\HWlZYOgWG5HNc7zLXXubIFv[2WmIFHQMVEheHKxbX;0[ZIh[WO2aY\peJk> MUeyN|M2OzZ7OR?=
H1650  NV3VU41KTnWwY4Tpc44hSXO|YYm= NYL6dGwxOTEEoN88UeKh M3\jUlEhcA>? M3f5d2ROW09? NFHGc5Vl\WO{ZXHz[ZMh[m:2aDDwdo91\WmwIHHu[EBuWk6DIHzleoVteyCxZjDFVmNEOSCrbjDwZYNtcXSjeHXsMYV5eG:|ZXVCpINmdGy| NFjhUWwzOzJ{OE[5Oi=>
H1703 NYq4SG9yTnWwY4Tpc44hSXO|YYm= M1vWflExyqEQvF5CpC=> NHjnWHcyKGh? MmfzSG1UVw>? M4\YUIRm[3KnYYPld{Bjd3SqIIDyc5RmcW5iYX7kJI1TVkFibHX2[Yx{KG:oIFXSR2MyKGmwIIDhZ4xqfGG6ZXyt[Zhxd3OnZNMgZ4VtdHN? NHzs[5gzOzJ{OE[5Oi=>
H1650  MoXVS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MlHqNVDDqM7:TdMg M1LGPFEhcA>? MYXEUXNQ MUflcohidmOnczDwZYNtcXSjeHXsMYlv\HWlZXSgZ5l1d3SxeHnjbZR6 NYOxOmpXOjN{Mki2PVY>
H1703 NGPEU5JIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M4PuNlExyqEQvF5CpC=> MoXpNUBp MmXwSG1UVw>? NHjlSHhmdmijbnPld{Bx[WOuaYThfIVtNWmwZIXj[YQh[3m2b4TvfIlkcXS7 MkDqNlMzOjh4OU[=

... Click to View More Cell Line Experimental Data

Assay
Methods Test Index PMID
Western blot
mTOR / p-S6K / S6K / p-S6 / p-AKT / p-MK2; 

PubMed: 26844273     


CRC cells were treated with 10 μM SB202190 for 2 h and analyzed for mTOR signaling and on-target inhibition of p38 by immunoblot. 

pJNK1 / pJNK2 / JNK1 / JNK2 ; 

PubMed: 18222647     


A549 cells were treated with DMSO control or with 10 µM of SB202190 for 0.5, 1, 2, 3, 4, or 6 hours, and pJNK and unphosphorylated JNK were detected as described. 

26844273 18222647
Immunofluorescence
p-p38 / MMP9; 

PubMed: 24479681     


Immunocytochemical staining and confocal microscopy confirmed that IL-1β increased activation of p38 (red), and MMP2 and MMP9 (green) expression in MKN-45 GA cells; these effects were blocked by p38 siRNA or the p38 inhibitor SB202190.

24479681
Growth inhibition assay
Cell viability ; 

PubMed: 26844273     


Top panel: CRC cells were treated with various concentrations of SB202190 for 48 h. Lower panel: CRC cells were treated with SB202190 at 10 μM for different times. Cell growth was measured by SRB assay (means ± s.d. in triplet, n = 3 in triplet).

26844273
In vivo Inhibiting p38 by administration of SB 202190 inhibits PV IgG-induced blister formation in the passive transfer mouse model. [5] In the endotoxin model of sepsis, SB 202190 treatment produces a statistically significant survival benefit compared with control. [8]

Protocol

Kinase Assay:

[1]

+ Expand

In vitro kinase assays:

The p38α and p38β are assayed in 25 mM Tris-HCl, pH 7.5, containing 0.1 mM EGTA, with myelin basic protein (0.33 mg/mL) as substrate. Assays are performed either manually for 10 minutes at 30 °C in 50 μL incubations using [γ-33P]ATP, or with a Biomek 2000 Laboratory Automation Workstation in a 96-well format for 40 minutes at ambient temperature in 25 μL incubations using [γ-33P]ATP. The concentrations of ATP and magnesium acetate are 0.1 mM and 10 mM respectively. All assays are initiated with MgATP. Manual assays are terminated by spotting aliquots of incubation on to phosphocellulose paper, followed by immersion in 50 mM phosphoric acid. Robotic assays are terminated by the addition of 5 μL of 0.5 M phosphoric acid before spotting aliquots on to P30 filter mats. All papers are then washed four times in 50 mM phosphoric acid to remove ATP, once in acetone (manual incubations) or methanol (robotic incubations), and then dried and counted for radioactivity.
Cell Research:

[2]

+ Expand
  • Cell lines: Jurkat, and HeLa
  • Concentrations: Dissolved in DMSO, final concentrations ~50 μM
  • Incubation Time: 24 hours
  • Method:

    Cells are serum-starved and then treated with different concentration of SB 202190 for 24 hours. Cell viability is assayed by either trypan blue exclusion or propidium iodide exclusion followed by flow cytometry analysis. The apoptotic nuclei are visualized by H33258 staining.


    (Only for Reference)
Animal Research:

[5]

+ Expand
  • Animal Models: C57BL/6J mice injected i.d. with a sterile solution of either control IgG or PV IgG
  • Formulation: Dissolved in DMSO, and diluted in saline
  • Dosages: 12.5 μg
  • Administration: Administered via i.d.
    (Only for Reference)

Solubility (25°C)

In vitro DMSO 66 mg/mL (199.19 mM)
Ethanol 12 mg/mL (36.21 mM)
Water Insoluble
In vivo Add solvents to the product individually and in order(Data is from Selleck tests instead of citations):
1% DMSO+30% polyethylene glycol+1% Tween 80
For best results, use promptly after mixing.
30 mg/mL

* Please note that Selleck tests the solubility of all compounds in-house, and the actual solubility may differ slightly from published values. This is normal and is due to slight batch-to-batch variations.

Chemical Information

Molecular Weight 331.34
Formula

C20H14N3OF

CAS No. 152121-30-7
Storage powder
in solvent
Synonyms N/A

Bio Calculators

Molarity Calculator

Molarity Calculator

Calculate the mass, volume or concentration required for a solution. The Selleck molarity calculator is based on the following equation:

Mass (mg) = Concentration (mM) × Volume (mL) × Molecular Weight (g/mol)

  • Mass
    Concentration
    Volume
    Molecular Weight

*When preparing stock solutions, please always use the batch-specific molecular weight of the product found on the via label and MSDS / COA (available on product pages).

Dilution Calculator

Dilution Calculator

Calculate the dilution required to prepare a stock solution. The Selleck dilution calculator is based on the following equation:

Concentration (start) x Volume (start) = Concentration (final) x Volume (final)

This equation is commonly abbreviated as: C1V1 = C2V2 ( Input Output )

  • C1
    V1
    C2
    V2

* When preparing stock solutions always use the batch-specific molecular weight of the product found on the vial label and MSDS / COA (available online).

The Serial Dilution Calculator Equation

  • Serial Dilutions

  • Computed Result

  • C1=C0/X C1: LOG(C1):
    C2=C1/X C2: LOG(C2):
    C3=C2/X C3: LOG(C3):
    C4=C3/X C4: LOG(C4):
    C5=C4/X C5: LOG(C5):
    C6=C5/X C6: LOG(C6):
    C7=C6/X C7: LOG(C7):
    C8=C7/X C8: LOG(C8):
Molecular Weight Calculator

Molecular Weight Calculator

Enter the chemical formula of a compound to calculate its molar mass and elemental composition:

Total Molecular Weight: g/mol

Tip: Chemical formula is case sensitive. C10H16N2O2 c10h16n2o2

Instructions to calculate molar mass (molecular weight) of a chemical compound:

To calculate molar mass of a chemical compound, please enter its chemical formula and click 'Calculate'.

Definitions of molecular mass, molecular weight, molar mass and molar weight:

Molecular mass (molecular weight) is the mass of one molecule of a substance and is expressed in the unified atomic mass units (u). (1 u is equal to 1/12 the mass of one atom of carbon-12)
Molar mass (molar weight) is the mass of one mole of a substance and is expressed in g/mol.

Molarity Calculator

Mass Concentration Volume Molecular Weight

Tech Support

Answers to questions you may have can be found in the inhibitor handling instructions. Topics include how to prepare stock solutions, how to store inhibitors, and issues that need special attention for cell-based assays and animal experiments.

Handling Instructions

Tel: +1-832-582-8158 Ext:3

If you have any other enquiries, please leave a message.

  • * Indicates a Required Field

p38 MAPK Signaling Pathway Map

p38 MAPK Inhibitors with Unique Features

Related p38 MAPK Products

Tags: buy SB202190 (FHPI) | SB202190 (FHPI) supplier | purchase SB202190 (FHPI) | SB202190 (FHPI) cost | SB202190 (FHPI) manufacturer | order SB202190 (FHPI) | SB202190 (FHPI) distributor
×
Cell Lines Assay Type Concentration Incubation Time Formulation Activity Description PMID